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Correspondence Hypothermia in Acute Coronary SyndromeBrain Salvage Versus Stent Thrombosis?To the Editor: Mild hypothermia therapy (HT), defined as body
temperature between 33°C and 34°C, is associated with im-
provement in neurological outcome after cardiac arrest. HT
reduces cerebral metabolism of glucose and oxygen consump-
tion with ensuing neuroprotection. In 2002, randomized clin-
ical trials in the setting of cardiac arrest validated the clinical
applicability of HT in comatose patients who were survivors of
an out-of-hospital cardiac arrest secondary to shockable
rhythms (1). As a result, the European Resuscitation Council
strongly recommends HT in these patients (2). Acute coronary
yndrome (ACS) is the leading cause of cardiac arrest; a timely
ardiac defibrillation and reperfusion therapy contribute to a
etter prognosis. The combination of early reperfusion and HT
as been reported as safe and effective (3). However, compli-
ations of HT have been described and include infections or
oagulation disorders, among others.
In this letter, we report our experience in patients with ACS and
ardiac arrest treated with HT and its association with a high
ncidence of stent thrombosis (ST). From January 2010 through
arch 2012, a total of 28 comatose patients (20 men, mean age:
5  18 years) were admitted to our hospital for out-of-hospital
cardiac arrest and were treated with HT. In all cases, the first
rhythm was ventricular fibrillation. HT was started in the emer-
gency area by the administration of 4°C saline, 30 ml/kg (maxi-
mum: 2 l) infused in 30 min. Infusion was stopped if the
temperature was  33.5°C. In the intensive care unit, patients
received standard treatment that included mechanical ventilation
and correction of cardiovascular instability. All patients were
Demographic and Procedure Characteristics of Patients With Mild HT UnderTable 1 Demographic and P o edure Characteristics of Pat ents With M
Patient
#
No. of
Stents Artery BMS/DES Size (mm) T
1 1 RCA BMS 3  18
2 2 RCA BMS 3  25/3  16
3 1 CXA BMS 3.5  25
4 2 LAD*/CXA DES 2.5  33/3  33
5 1 LAD BMS 3.5  18
6 1 LAD BMS 3.5  12
7 1 LAD BMS 2.5  18
8 1 LAD DES 3.5  20
9 1 LAD BMS 2.5  14
10 1 LAD BMS 2.5  19
11 4 RCA BMS 3  18/3.5 
8/2.5  13/2.25  13
*The thrombosed stent was the one placed in the LAD.
ASA acetyl salycilic acid; BMS bare-metal stent; CXA circumflex coronary artery; DES drug-e
LD  loading dose; pPCI  primary percutaneous coronary intervention; RCA  right coronary artery.sedated with an infusion of midazolam and morphine at doses that
were adjusted for the management of mechanical ventilation.
Neuromuscular relaxation was achieved with cisatracurium infu-
sion to avoid muscular tremor. A urinary catheter with temperature
sensor (Foley catheter, Rüsch sensor series 400 [silicon], Curity,
Tyco, Athione, Ireland) was implanted. The extracorporeal HT
system (Medivance Arctic Sun System, Louisville, Colorado) was
used to control temperature. All patients reached 33°C fewer than
8 h from cardiac arrest, and this temperature was maintained for
24 h. Warming took place gradually in 24 to 30 h, with a rate of
0.10 to 0.15°C/h.
Coronary angiography was performed in 18 (65%) patients, of
whom 15 had a final ACS diagnosis. Of them, 10 patients (66%)
had ST-segment elevation myocardial infarction; percutaneous
coronary intervention (PCI) was carried out in 11 patients. The
mean interval from door to balloon was 78 39 min. A total of 16
stents were implanted: 13 bare-metal stents and 3 drug-eluting
stents. Antiplatelet therapy did not differ from the usual practice
with dual antiplatelet therapy that included aspirin (maintenance:
100 mg/day), clopidogrel (maintenance: 75 mg/day) (loading dose
in Table 1), and anticoagulation with Na heparin intravenously in
all patients and glycoprotein IIb/IIIa receptor blockers if a large
thrombus was seen in the catheterization laboratory (see Table 1).
A total of 5 (31.2%) ST occurred during follow-up: 1 acute and 4
subacute. Four of them were bare-metal stents; all of them were in
ST-segment elevation myocardial infarction patients. All were
definite ST. In 4 patients, ST was diagnosed after coronary
angiography, and in the last one, the diagnosis was made at
pPCIUndergoing pPCI
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Yeluting stent; GP glycoprotein; HT hypothermia therapy; LAD left anterior descending artery;
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February 12, 2013:686–91autopsy. In all patients, ST caused myocardial infarction. One
patient died of ischemic electric storm after ST and another died
of pulmonary infection after a diagnosis of anoxic encephalopathy
was made. The other 3 patients were discharged without brain
damage. The mean time from primary PCI to thrombotic event
was 174  146 h (range 8 to 376 h). Furthermore, 2 patients had
a thrombotic complication not related to PCI: 1 patient had a
pulmonary embolism, and another patient had a deep vein throm-
bosis; both occurred before discharge. There were no bleeding
complications.
During the same period, we performed 2,737 PCI (42.1%
pPCI). Our rate of definite ST in this period in patients without
HT was 0.44% (0.7% among patient undergoing pPCI). We are
concerned about the higher than expected rate of ST in patients
with pPCI treated with HT. Recently, Ibrahim et al. (4) described
a 14.8% rate of ST among 27 patients treated with HT and PCI.
In this series, the vasodilator stimulated phosphoprotein index was
significantly higher in patients with HT compared with a control
group without HT. There are recent experimental data that
correlate HT with an increase in platelet activation, with platelet
adenosine diphosphate receptor P2Y12 playing a central role (5).
Because platelet adenosine diphosphate receptor P2Y12 is a pivotal
target for antiplatelet treatment in ACS, particularly in patients
with an implanted stent, we hypothesize that the dual antiplatelet
therapy used may be inefficient in hypothermic conditions. More-
over, metabolic conversion of clopidogrel in the liver may be
reduced in hypothermia conditions. Besides, patients with HT are
mechanically ventilated and require nasogastric intubation for the
administration of dual antiplatelet therapy and often need correc-
tion for cardiovascular instability. Under these conditions, absorp-
tion of antiplatelet drugs may be reduced, and prothrombotic
status resulting from a critical state after cardiac arrest can not be
ruled out. Further studies are needed to determine why hypother-
mia is associated with increased rate of ST.
In conclusion, in our practice, HT treatment is associated with
a disturbingly high number of cases of ST, despite guideline-
indicated antithrombotic therapy. New research is needed to
determine the cause of these episodes, as well as the optimal
antithrombotic therapy in these patients.
Transcatheter Aortic Valve Implantat
standard” therapy in patients with severe aortic stenosis (3).Diego Penela, MD†
Marta Magaldi, MD‡
Jaume Fontanals, MD, PhD‡
Victoria Martin, MD, PhD†
Ander Regueiro, MD†
José Tomas Ortiz, MD, PhD†
Xavier Bosch, MD, PhD†
Manel Sabaté, MD, PhD†
*Magda Heras, MD, PhD†
*Department of Cardiology
Thorax Institute
Hospital Clinic
University of Barcelona
Villarroel, 170
08036 Barcelona
Spain
E-mail: mheras@clinic.ub.es
http://dx.doi.org/10.1016/j.jacc.2012.10.029
From the †Department of Cardiology, Thorax Center, Hospital
Clinic, University of Barcelona, Barcelona, Spain; and the
‡Department of Anaesthesia, Hospital Clinic, University of
Barcelona, Barcelona, Spain
REFERENCES
1. Holzer M, Cerchiari E, Martens P, et al. Mild therapeutic hypothermia
to improve the neurologic outcome after cardiac arrest. N Engl J Med
2002;346:549–56.
2. Nolan JP, Soar J, Zideman DA, et al. European Resuscitation Council
Guidelines for Resuscitation 2010 section 1. Executive summary.
Resuscitation 2010;81:1219–76.
3. Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-term
prognosis following resuscitation from out of hospital cardiac arrest: role
of percutaneous coronary intervention and therapeutic hypothermia.
J Am Coll Cardiol 2012;60:21–7.
4. Ibrahim K. Increased rate of stent thrombosis due to clopidogrel
resistance in patients in therapeutic hypothermia after sudden cardiac
death. Eur Heart J 2011;32 (Suppl): 252.
5. Straub A, Krajewski S, Hohmann JD, et al. Evidence of platelet
activation at medically used hypothermia and mechanistic data indicat-
ing ADP as a key mediator and therapeutic target. Arterioscler Thromb
Vasc Biol 2011;31:1607–16.CORRESPONDENCE
Research Correspondence
Heyde’s Syndrome Incidence and Outcome in Patients Undergoing
ionTo the Editor: Heyde’s syndrome is the association between calcific
aortic stenosis and gastrointestinal bleeding (GIB) due to an-
giodysplasia. This rare relationship is observed in approximately
3% of patients with aortic stenosis, and it was first suggested by
Edward J. Heyde in 1958 (1). The pathogenesis of Heyde’s
syndrome involves an acquired von Willebrand factor (vWF)
deficiency secondary to aortic stenosis and other degenerative
disease in elderly patients with concomitant GIB (Fig. 1) (2).
Surgical aortic valve replacement (SAVR) is considered the “goldTherefore, we hypothesized that transcatheter aortic valve implan-
tation (TAVI) may also be effective to treat Heyde’s syndrome
patients at high risk for SAVR. To test this hypothesis, we
retrospectively analyzed all patients treated for TAVI between
November 2007 and February 2012. Heyde’s syndrome was
diagnosed in the presence of both severe aortic stenosis and a
history of recurrent GIB with an instrumental diagnosis of
angiodysplasia (documented by colonoscopy and esophagogas-
troduodenoscopy). Upper and lower GIB of unknown origin
and/or related to other causes was defined as bleeding not related
